GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lifecore Biomedical Inc (NAS:LFCR) » Definitions » Current Ratio

Lifecore Biomedical (Lifecore Biomedical) Current Ratio

: 2.39 (As of May. 2023)
View and export this data going back to 1996. Start your Free Trial

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Lifecore Biomedical's current ratio for the quarter that ended in May. 2023 was 2.39.

Lifecore Biomedical has a current ratio of 2.39. It generally indicates good short-term financial strength.

The historical rank and industry rank for Lifecore Biomedical's Current Ratio or its related term are showing as below:

LFCR' s Current Ratio Range Over the Past 10 Years
Min: 0.66   Med: 1.5   Max: 2.39
Current: 2.39

During the past 13 years, Lifecore Biomedical's highest Current Ratio was 2.39. The lowest was 0.66. And the median was 1.50.

LFCR's Current Ratio is ranked better than
61.06% of 1076 companies
in the Drug Manufacturers industry
Industry Median: 1.915 vs LFCR: 2.39

Lifecore Biomedical Current Ratio Historical Data

The historical data trend for Lifecore Biomedical's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifecore Biomedical Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Current Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.96 1.46 0.66 2.39

Lifecore Biomedical Quarterly Data
Aug18 Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23
Current Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.66 1.40 0.65 2.35 2.39

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Current Ratio Distribution

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Current Ratio distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Current Ratio falls into.



Lifecore Biomedical Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Lifecore Biomedical's Current Ratio for the fiscal year that ended in May. 2023 is calculated as

Current Ratio (A: May. 2023 )=Total Current Assets (A: May. 2023 )/Total Current Liabilities (A: May. 2023 )
=93.875/39.289
=2.39

Lifecore Biomedical's Current Ratio for the quarter that ended in May. 2023 is calculated as

Current Ratio (Q: May. 2023 )=Total Current Assets (Q: May. 2023 )/Total Current Liabilities (Q: May. 2023 )
=93.875/39.289
=2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lifecore Biomedical  (NAS:LFCR) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Lifecore Biomedical Current Ratio Related Terms

Thank you for viewing the detailed overview of Lifecore Biomedical's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifecore Biomedical (Lifecore Biomedical) Business Description

Traded in Other Exchanges
N/A
Address
3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid.
Executives
Raymond T. White director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Holdings, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. Ii director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners, L.p. I director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Legion Partners Asset Management, Llc director 12121 WILSHIRE BLVD., SUITE 1240, LOS ANGELES CA 90025
Christopher S Kiper director 12121 WILSHIRE BLVD, SUITE 1240, LOS ANGELES CA 90025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Wynnefield Partners Small Cap Value Lp I 10 percent owner 450 SEVENTH AVENUE, SUITE 509, NEW YORK NY 10123
Raymond H Diradoorian director C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Joshua Schechter director C/O THE PANTRY, INC., 305 GREGSON DRIVE, CARY NC 27511
Patrick D Walsh director 14282 FRANKLIN AVE., TUSTIN CA 92780
John D Morberg officer: Chief Financial Officer C/O LANDEC CORPORATION, 2811 AIRPARK DRIVE, SANTA MARIA CA 93455
Albert D. Bolles director CONAGRA FOODS, INC., ONE CONAGRA DRIVE, MS 1-330, OMAHA NE 68102
James G Hall officer: Executive Vice President 3515 LYMAN BLVD., CHASKA MN 55318

Lifecore Biomedical (Lifecore Biomedical) Headlines